Is Madrigal Pharmaceuticals (MDGL) Fully Valued Ahead Of Its July 30 Earnings?

Madrigal Pharmaceuticals (MDGL) has set July 30, 2026 as the date for its second quarter 2026 earnings release, with management hosting a webcast before the U.S. market opens to discuss the results.

See our latest analysis for Madrigal Pharmaceuticals.

At a share price of $545.53, Madrigal Pharmaceuticals has seen short term share price momentum cool slightly, although its 30 day share price return of 8.85% sits alongside a 1 year total shareholder return of 56.43% and a 5 year total shareholder return of roughly 6x.

If Madrigal’s recent move has you thinking about other potential opportunities in healthcare, it could be a good moment to scan 39 healthcare AI stocks.

Madrigal Pharmaceuticals now has an approved MASH drug, meaningful revenue and a market value of about US$12.7b. Yet after the latest share price swing, the real tension is clear: does that strength already sit fully in the price?

Most Popular Narrative: 19.6% Undervalued

The most followed narrative currently places Madrigal Pharmaceuticals' fair value at $678.71, compared with the latest close at $545.53, highlighting a meaningful valuation gap that hinges heavily on Rezdiffra's long run opportunity.

The rapid uptake and long-term patent protection of Rezdiffra, supported by a new U.S. patent that extends exclusivity to 2045, provides decades of protected revenue opportunity; this increases the likelihood of sustained top-line growth and supports margin expansion due to extended pricing power.

Read the complete narrative.

Want to see what sits behind that confidence in Madrigal Pharmaceuticals? The narrative leans on aggressive revenue expansion, rising margins and a richer earnings multiple than the wider biotech sector. The exact mix of growth, profitability and valuation expectations may surprise you.

Result: Fair Value of $678.71 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Madrigal Pharmaceuticals still faces meaningful risks, including reliance on Rezdiffra and the potential for tougher pricing and reimbursement that could pressure margins and growth expectations.

Find out about the key risks to this Madrigal Pharmaceuticals narrative.

Next Steps

If this Madrigal Pharmaceuticals story sounds compelling, do not leave the decision solely to headline numbers. Instead, move quickly to review the full picture and weigh the company's 1 or more potential rewards using the 3 key rewards.

Looking for more investment ideas beyond Madrigal Pharmaceuticals?

If Madrigal Pharmaceuticals has sharpened your interest, do not stop here. Use Simply Wall Street's screener to uncover other stocks that could fit your portfolio goals.

• Target potential mispricings by scanning for companies that combine quality fundamentals with appealing valuations through the 49 high quality undervalued stocks.
• Strengthen your income stream by reviewing companies highlighted in the 8 dividend fortresses that pair higher yields with resilient cash flows.
• Protect your capital by focusing on companies flagged in the 82 resilient stocks with low risk scores that score well on balance sheet strength and risk measures.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com